Drug Target Review

APRIL 5, 2024

However, there is significant variability within the various CHO cell lines, and CDMOs often have differing levels of success in optimising their cells for protein production. Skilled CDMOs can also locate or create favourable genomic microenvironments where transcription factors are efficiently recruited, further boosting protein production.

Protein Production 96

Protein Production Protein Expression Bioinformatics Production 96

DrugBank

MARCH 15, 2023

The moment you decide which DrugBank license or products best suit your needs isn’t the final step in our relationship, it is just the beginning. Depending on your unique needs, license*, and project goals, you might interact with all of them firsthand, or you might be off and running with just a little help from one team.

Licensing 52

Licensing Licensing International Bioinformatics 52

The Pharma Data

JULY 27, 2021

Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.

Production 52

Production Clinical Trials Government Disease 52

The Pharma Data

DECEMBER 27, 2020

Tyvaso DPI, previously referred to as Treprostinil Technosphere ® , is an investigational drug-device combination product comprised of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler. United Therapeutics is developing Tyvaso DPI under a collaboration and license agreement with MannKind Corporation.

FDA 52

FDA Bioinformatics Disease Production 52

The Pharma Data

OCTOBER 27, 2020

“As our core business continues to perform well, we have a solid footing to enter 2021 with several key product launches including the potential INCREASE product label expansion for Tyvaso, the Remunity Pump for Remodulin, and the Implantable System for Remodulin,” said Martine Rothblatt , Ph.D., SILVER SPRING, Md.

FDA 40

FDA Production Licensing Licensing 40

Drug Target Review

FEBRUARY 11, 2025

The ongoing transformation is leading to the gradual replacement of traditional processes with more dynamic and data-driven models, with the primary objective of improving clinical success rates and productivity. Clinical bioinformatics desiderata for Molecular Tumor Boards. Refining the impact of genetic evidence on clinical success.

Drug Development 59

Drug Development Bioinformatics Drugs Small Molecule 59

Drug Target Review

MARCH 13, 2025

His leadership has driven international commercial success in areas including image analysis, data management, bioinformatics, advanced clinical trial data analysis leveraging machine learning and federated learning. FDA Proposes Framework to Advance Credibility of AI Models Used for Drug and Biological Product Submissions [Internet].

Drug Development 59

Drug Development Science Clinical Trials FDA 59